Itacitinib for the Prevention of Graft Versus Host Disease
Status:
Not yet recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies if itacitinib plus standard of care treatment may help prevent
graft-versus-host-disease (GVHD) in patients who have received an allogeneic (donor) stem
cell transplant. An allogeneic transplant uses blood-making cells from a family member or
unrelated donor to remove and replace a patient's abnormal blood cells. Sometimes the
transplanted cells from a donor can attack the body's normal cells (called graft-versus-host
disease). Giving itacitinib with standard of care treatment after the transplant may stop
this from happening.